Ralliant (NYSE:RAL) Stock Rating Upgraded by Zacks Research

Ralliant (NYSE:RAL) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other research firms also recently weighed in on RAL. Citigroup increased their target price on Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Barclays increased their price objective on shares of Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. Royal Bank Of Canada raised their target price on shares of Ralliant from $47.00 to $64.00 and gave the stock a “sector perform” rating in a research report on Wednesday, May 13th. Finally, Morgan Stanley boosted their target price on shares of Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a report on Tuesday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $69.00.

Ralliant Stock Down 2.3%

RAL stock opened at $71.93 on Tuesday. The company has a 50 day moving average price of $59.71 and a two-hundred day moving average price of $51.69. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. The stock has a market capitalization of $8.05 billion and a P/E ratio of -6.57. Ralliant has a one year low of $37.27 and a one year high of $75.41.

Ralliant (NYSE:RAL) last issued its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The company had revenue of $534.60 million for the quarter. Ralliant’s revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, sell-side analysts expect that Ralliant will post 2.64 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of RAL. Allworth Financial LP grew its stake in Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after buying an additional 293 shares during the period. Rothschild Investment LLC raised its stake in shares of Ralliant by 98.1% in the 4th quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock valued at $31,000 after acquiring an additional 303 shares during the period. Keybank National Association OH raised its stake in shares of Ralliant by 1.6% in the 4th quarter. Keybank National Association OH now owns 19,667 shares of the company’s stock valued at $1,001,000 after acquiring an additional 305 shares during the period. UMB Bank n.a. lifted its holdings in shares of Ralliant by 49.6% during the 4th quarter. UMB Bank n.a. now owns 983 shares of the company’s stock valued at $50,000 after acquiring an additional 326 shares in the last quarter. Finally, Maryland State Retirement & Pension System lifted its holdings in shares of Ralliant by 1.5% during the 4th quarter. Maryland State Retirement & Pension System now owns 21,940 shares of the company’s stock valued at $1,117,000 after acquiring an additional 329 shares in the last quarter.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.